IRF2 and neoplasm: It has been well documented that IRF2 expression by CD8+ tumor-infiltrating lymphocytes drives T cell exhaustion, and irf2−/− CD8+ T cells expressed lower levels of inhibitory receptors including PD-1 as compared with WT CD8+ T cells [47,71].